Analysis of sequence requirements for biological activity of cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein

被引:40
作者
Mori, T
Shoemaker, RH
Gulakowski, RJ
Krepps, BL
McMahon, JB
Gustafson, KR
Pannell, LK
Boyd, MR
机构
[1] NCI,FREDERICK CANC RES & DEV CTR,LAB DRUG DISCOVERY RES & DEV,DEV THERAPEUT PROGRAM,FREDERICK,MD 21702
[2] NIDDK,ANALYT CHEM LAB,BETHESDA,MD 20892
关键词
D O I
10.1006/bbrc.1997.7202
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Site-directed mutagenesis of DNA constructs coding for the novel, HIV-inactivating proteins cyanovirin-N (CV-N) and FLAG-cyanovirin-N (F-CV-N) was performed using mutagenic oligonucleotide primers in the polymerase chain reaction or by a restriction site elimination maneuver. The mutant constructs were expressed in Escherichia coli and the recombinant protein products were tested for binding to the HIV surface envelope glycoprotein gp120 and for antiviral activity against infectious HIV. Results showed an overall very high correlation (r(2) > 0.9) between the relative gp120 binding affinities and the anti-HIV activities of CV-N, F-CV-N, and the various mutants. An outlier, however, was a mutant which lacked one of the internal disulfide linkages normally present in CV-N and which showed modest gp120 binding but no antiviral activity against HIV. These findings are consistent with the view that gp120 binding is a necessary but not sufficient requirement for the HIV-inactivating activity of CV-N and related proteins; the sequence specificities for gp120 binding and anti-HIV activity are not identical. (C) 1997 Academic Press.
引用
收藏
页码:218 / 222
页数:5
相关论文
共 9 条
[1]   Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: Potential applications to microbicide development [J].
Boyd, MR ;
Gustafson, KR ;
McMahon, JB ;
Shoemaker, RH ;
OKeefe, BR ;
Mori, T ;
Gulakowski, RJ ;
Wu, L ;
Rivera, MI ;
Laurencot, CM ;
Currens, MJ ;
Cardellina, JH ;
Buckheit, RW ;
Nara, PL ;
Pannell, LK ;
Sowder, RC ;
Henderson, LE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) :1521-1530
[2]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[3]   HIGH-CONCENTRATIONS OF RECOMBINANT SOLUBLE CD4 ARE REQUIRED TO NEUTRALIZE PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES [J].
DAAR, ES ;
LI, XL ;
MOUDGIL, T ;
HO, DD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (17) :6574-6578
[4]   A SEMIAUTOMATED MULTIPARAMETER APPROACH FOR ANTI-HIV DRUG SCREENING [J].
GULAKOWSKI, RJ ;
MCMAHON, JB ;
STALEY, PG ;
MORAN, RA ;
BOYD, MR .
JOURNAL OF VIROLOGICAL METHODS, 1991, 33 (1-2) :87-100
[5]  
GUSTAFSON KR, 1997, UNPUB
[6]  
HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205
[7]   VIRIONS OF PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES RESISTANT TO SOLUBLE CD4 (SCD4) NEUTRALIZATION DIFFER IN SCD4 BINDING AND GLYCOPROTEIN GP120 RETENTION FROM SCD4-SENSITIVE ISOLATES [J].
MOORE, JP ;
MCKEATING, JA ;
HUANG, YX ;
ASHKENAZI, A ;
HO, DD .
JOURNAL OF VIROLOGY, 1992, 66 (01) :235-243
[8]  
MOVRA NR, 1980, J BIOL CHEM, V255, P27
[9]   INCREASE IN SENSITIVITY TO SOLUBLE CD4 BY PRIMARY HIV TYPE-1 ISOLATES AFTER PASSAGE THROUGH C8166 CELLS - ASSOCIATION WITH SEQUENCE DIFFERENCES IN THE FIRST CONSTANT (C1) REGION OF GLYCOPROTEIN-120 [J].
ORLOFF, SL ;
BANDEA, CI ;
KENNEDY, MS ;
ALLAWAY, GP ;
MADDON, PJ ;
MCDOUGAL, JS .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 (03) :335-342